Logo image of BURU

NUBURU INC (BURU) Stock Fundamental Analysis

USA - NYSEARCA:BURU - US67021W3016 - Common Stock

0.2231 USD
+0 (+0.86%)
Last: 10/3/2025, 8:26:51 PM
0.2195 USD
0 (-1.61%)
After Hours: 10/3/2025, 8:26:51 PM
Fundamental Rating

0

Overall BURU gets a fundamental rating of 0 out of 10. We evaluated BURU against 129 industry peers in the Machinery industry. BURU has a bad profitability rating. Also its financial health evaluation is rather negative. BURU is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

BURU had negative earnings in the past year.
BURU had a negative operating cash flow in the past year.
BURU Yearly Net Income VS EBIT VS OCF VS FCFBURU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

BURU's Return On Assets of -271.61% is on the low side compared to the rest of the industry. BURU is outperformed by 94.57% of its industry peers.
Industry RankSector Rank
ROA -271.61%
ROE N/A
ROIC N/A
ROA(3y)-130.37%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BURU Yearly ROA, ROE, ROICBURU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 500 -500

1.3 Margins

BURU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BURU Yearly Profit, Operating, Gross MarginsBURU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -500 -1K -1.5K -2K

0

2. Health

2.1 Basic Checks

BURU does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BURU has more shares outstanding
The debt/assets ratio for BURU is higher compared to a year ago.
BURU Yearly Shares OutstandingBURU Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M
BURU Yearly Total Debt VS Total AssetsBURU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -24.74, we must say that BURU is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BURU (-24.74) is worse than 93.80% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -24.74
ROIC/WACCN/A
WACC9.39%
BURU Yearly LT Debt VS Equity VS FCFBURU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

A Current Ratio of 0.16 indicates that BURU may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.16, BURU is doing worse than 95.35% of the companies in the same industry.
A Quick Ratio of 0.03 indicates that BURU may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.03, BURU is doing worse than 96.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.03
BURU Yearly Current Assets VS Current LiabilitesBURU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 5M 10M

2

3. Growth

3.1 Past

BURU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.62%.
The Revenue has decreased by -6.32% in the past year.
Measured over the past years, BURU shows a very strong growth in Revenue. The Revenue has been growing by 44.58% on average per year.
EPS 1Y (TTM)-10.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.74%
Revenue 1Y (TTM)-6.32%
Revenue growth 3Y44.58%
Revenue growth 5YN/A
Sales Q2Q%-80.11%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BURU Yearly Revenue VS EstimatesBURU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 500K 1M 1.5M 2M

0

4. Valuation

4.1 Price/Earnings Ratio

BURU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BURU Price Earnings VS Forward Price EarningsBURU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BURU Per share dataBURU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

BURU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NUBURU INC

NYSEARCA:BURU (10/3/2025, 8:26:51 PM)

After market: 0.2195 0 (-1.61%)

0.2231

+0 (+0.86%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)08-12 2025-08-12
Earnings (Next)11-12 2025-11-12
Inst Owners0.58%
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner Change0%
Market Cap29.49M
AnalystsN/A
Price TargetN/A
Short Float %10.06%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.3
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0.01
BVpS-0.1
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -271.61%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-130.37%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 130.82%
Cap/Sales 48.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.16
Quick Ratio 0.03
Altman-Z -24.74
F-Score2
WACC9.39%
ROIC/WACCN/A
Cap/Depr(3y)143.01%
Cap/Depr(5y)N/A
Cap/Sales(3y)68.88%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.74%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.32%
Revenue growth 3Y44.58%
Revenue growth 5YN/A
Sales Q2Q%-80.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-73.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.46%
OCF growth 3YN/A
OCF growth 5YN/A